54
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      PTGER1 and PTGER2 receptors mediate regulation of progesterone synthesis and type 1 11β-hydroxysteroid dehydrogenase activity by prostaglandin E 2 in human granulosa–lutein cells

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In luteinizing granulosa cells, prostaglandin E 2 (PGE 2) can exert luteotrophic actions, apparently via the cAMP signalling pathway. In addition to stimulating progesterone synthesis, PGE 2 can also stimulate oxidation of the physiological glucocorticoid, cortisol, to its inactive metabolite, cortisone, by the type 1 11β-hydroxysteroid dehydrogenase (11βHSD1) enzyme in human granulosa–lutein cells. Having previously shown these human ovarian cells to express functional G-protein coupled, E-series prostaglandin (PTGER)1, PTGER2 and PTGER4 receptors, the aim of this study was to delineate the roles of PTGER1 and PTGER2 receptors in mediating the effects of PGE 2 on steroidogenesis and cortisol metabolism in human granulosa–lutein cells. PGE 2-stimulated concentration-dependent increases in both progesterone production and cAMP accumulation (by 1·9±0·1- and 18·7±6·8-fold respectively at 3000 nM PGE 2). While a selective PTGER1 antagonist, SC19220, could partially inhibit the steroidogenic response to PGE 2 (by 55·9±4·1% at 1000 nM PGE 2), co-treatment with AH6809, a mixed PTGER1/PTGER2 receptor antagonist, completely abolished the stimulation of progesterone synthesis at all tested concentrations of PGE 2 and suppressed the stimulation of cAMP accumulation. Both PGE 2 and butaprost (a preferential PTGER2 receptor agonist) stimulated concentration-dependent increases in cortisol oxidation by 11βHSD1 (by 42·5±3·1 and 40·0±3·0% respectively, at PGE 2 and butaprost concentrations of 1000 nM). Co-treatment with SC19220 enhanced the ability of both PGE 2 and butaprost to stimulate 11βHSD1 activity (by 30·2±0·2 and 30·5±0·6% respectively), whereas co-treatment with AH6809 completely abolished the 11βHSD1 responses to PGE 2 and butaprost. These findings implicate the PTGER2 receptor–cAMP signalling pathway in the stimulation of progesterone production and 11βHSD1 activity by PGE 2 in human granulosa–lutein cells.

          Related collections

          Most cited references54

          • Record: found
          • Abstract: found
          • Article: not found

          Prostanoid receptors: structures, properties, and functions.

          Prostanoids are the cyclooxygenase metabolites of arachidonic acid and include prostaglandin (PG) D(2), PGE(2), PGF(2alpha), PGI(2), and thromboxne A(2). They are synthesized and released upon cell stimulation and act on cells in the vicinity of their synthesis to exert their actions. Receptors mediating the actions of prostanoids were recently identified and cloned. They are G protein-coupled receptors with seven transmembrane domains. There are eight types and subtypes of prostanoid receptors that are encoded by different genes but as a whole constitute a subfamily in the superfamily of the rhodopsin-type receptors. Each of the receptors was expressed in cultured cells, and its ligand-binding properties and signal transduction pathways were characterized. Moreover, domains and amino acid residues conferring the specificities of ligand binding and signal transduction are being clarified. Information also is accumulating as to the distribution of these receptors in the body. It is also becoming clear for some types of receptors how expression of their genes is regulated. Furthermore, the gene for each of the eight types of prostanoid receptor has been disrupted, and mice deficient in each type of receptor are being examined to identify and assess the roles played by each receptor under various physiological and pathophysiological conditions. In this article, we summarize these findings and attempt to give an overview of the current status of research on the prostanoid receptors.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Failure of parturition in mice lacking the prostaglandin F receptor.

            Mice lacking the gene encoding the receptor for prostaglandin F2alpha (FP) developed normally but were unable to deliver normal fetuses at term. Although these FP-deficient mice showed no abnormality in the estrous cycle, ovulation, fertilization, or implantation, they did not respond to exogenous oxytocin because of the lack of induction of oxytocin receptor (a proposed triggering event in parturition), and they did not show the normal decline of serum progesterone concentrations that precedes parturition. Ovariectomy at day 19 of pregnancy restored induction of the oxytocin receptor and permitted successful delivery in the FP-deficient mice. These results indicate that parturition is initiated when prostaglandin F2alpha interacts with FP in ovarian luteal cells of the pregnant mice to induce luteolysis.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes.

                Bookmark

                Author and article information

                Journal
                J Endocrinol
                JOE
                The Journal of Endocrinology
                Society for Endocrinology (Bristol )
                0022-0795
                1479-6805
                September 2007
                13 June 2007
                : 194
                : 3
                : 595-602
                Affiliations
                [1 ]simpleDepartment of Biochemistry and Molecular Biology, Royal Free and University College Medical School, University College London Rowland Hill Street, London NW3 2PFUK
                [2 ]simpleDepartment of Veterinary Basic Science, Royal Veterinary College Royal College Street, London NW1 0TUUK
                [3 ]simpleDepartment of Clinical Science at South Bristol (Obstetrics and Gynaecology), University of Bristol Dorothy Hodgkin Building, Whitson Street, Bristol BS1 3NYUK
                [4 ]simpleDivision of Clinical Developmental Sciences, Academic Section of Obstetrics & Gynaecology, Centre for Developmental and Endocrine Signalling, St George's University of London Cranmer Terrace Tooting, London SW17 0REUK
                Author notes
                (Requests for offprints should be addressed to A E Michael; Email: tony.michael@ 123456sgul.ac.uk )
                []

                (C Chandras is now at Developmental Biology, Foundation for Biomedical Research of the Academy of Athens, 11527 Athens, Greece)

                Article
                JOE070128
                10.1677/JOE-07-0128
                2040272
                17761898
                fed93ce5-f8d5-4538-9921-ac09bd324ea5
                © 2007 Society for Endocrinology

                This is an Open Access article distributed under the terms of the Society for Endocrinology's Re-use Licence which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 31 May 2007
                : 10 June 2007
                Funding
                Funded by: Wellcome Trust
                Award ID: WT056630
                Categories
                Regular Papers

                Endocrinology & Diabetes
                Endocrinology & Diabetes

                Comments

                Comment on this article